MG-132 化学構造
分子量: 475.62

高品質保証

文献中の引用(42)

カスタマーフィードバック(9)

Quality Control & MSDS

製品説明

  • Compare Proteasome Inhibitors
    Proteasome製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 MG-132は、100nMのIC50によるプロテアソームの強力な阻害剤です。
ターゲット

Proteasome

IC50

100 nM [1]

In vitro試験 MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cells MVHGeY5kfGmxbjDBd5NigQ>? NF70boMzPSEQvF2= M1jPTWROW09? MljaTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvOSEQvF2= M3f3W|I1Pjl5NEm2
HL-60 M3vhR2N6fG:2b4jpZ{BCe3OjeR?= NYm1S4tqPDBizszN M3\WNlQ5KGh? NHXNZnNFVVOR MYnJR|UxRDFyIN88US=> NIrS[oszPDZ7N{S5Oi=>
SMMC-7721 M{LuRmN6fG:2b4jpZ{BCe3OjeR?= NYfrdos5PDBizszN NFP0WHI1QCCq MmfKSG1UVw>? MUXJR|UxRTdwMTFOwG0> NHzUfWozPDZ7N{S5Oi=>
A-549 NEH6flJEgXSxdH;4bYMhSXO|YYm= MmnoOFAh|ryP M4XaeFQ5KGh? NG[zOItFVVOR NXuyUohtUUN3MEyxNEDPxE1? NYTRfZhjOjR4OUe0PVY>
MCF-7 M3z1b2N6fG:2b4jpZ{BCe3OjeR?= MUK0NEDPxE1? Mlz6OFghcA>? NHTkRYFFVVOR NHy2NpNKSzVyPUeuN{DPxE1? NXrhVFREOjR4OUe0PVY>
SW-480 NYPSc2I6S3m2b4TvfIlkKEG|c3H5 NEPLbGQ1OCEQvF2= M2jJOVQ5KGh? MXLEUXNQ MUjJR|UxRTRizszN M3u3WlI1Pjl5NEm2
NCI-H929 M3;mUGN6fG:2b4jpZ{BCe3OjeR?= MoLkNUDPxE1? MWS3NkBp MV3EUXNQ M1y5eGlEPTB;MD6xO{DPxE1? M3vKS|I1PjJ3MEi4
293T MVLDfZRwfG:6aXOgRZN{[Xl? M1T6TVExKM7:TR?= NITZTlY4OiCq M3nNRWROW09? MlrFTWM2ODx{IN88US=> M1jYclI1PjJ3MEi4
293T NFL3ZphHfW6ldHnvckBCe3OjeR?= MnrCNVAh|ryP MlnJNlQhcA>? NFrrUoFFVVOR MXXNc4RmemG2ZXz5JIlv\HWlZYOgbIVifC2|aH;jb{Ah MUeyOFYzPTB6OB?=
HeLa M4fYWGtqdmG|ZTDBd5NigQ>? NHThTWcyOCEQvF2= NHXo[G0yKGh? NVz3fY5DTE2VTx?= MVTJcoR2[2W|IGDBVnAh[2ynYY\h[4Uh[nliaX7obYJqfGmwZzDwdo9{\WG|b33lJIFkfGm4aYT5 NU\uTJlyOjR|MkG4N|M>
MDA-MB-231 M1XXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT2NUDPxE1? NHjrbI84OiCq MlXhSG1UVw>? M4LTZ2lEPTB;MD6xPEDPxE1? NYHpVW9vOjRzNUOyNFY>
MCF-7 M{f4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jnUVEh|ryP M2OxdlczKGh? M{LveGROW09? MWfJR|UxRTBwMUOg{txO MlXvNlQyPTN{ME[=
MCF10A M1XsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLHOlJWOSEQvF2= MWG3NkBp MXvEUXNQ NVvBOoU1UUN3ME2wMlI6KM7:TR?= MkTGNlQyPTN{ME[=
HEK-293 NGLRW|JMcW6jc3WgRZN{[Xl? M4X2WlIh[W6mIEKwJO69VQ>? NFnjXXQzKGh? NWj1NI5uTE2VTx?= NVXmTlhnUW6qaXLpeJMhS2iWLVygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDlibl2g MnfUNlM2PDB5OUC=
Calu6 NFPLOmZHfW6ldHnvckBCe3OjeR?= MUKxNEDPxE1? MmnuNVghcA>? M{ezeWROW09? NXTQeG9FW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> NF\5eFczOzVyNkS4Oi=>
IFN-gamma-induced RAW264.7 MorWSpVv[3Srb36gRZN{[Xl? NWfHN3h5TE2VTx?= MUjJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN MnHBNlIzPzd{N{e=
IPC227F MWnDfZRwfG:6aXOgRZN{[Xl? M3HNNFEh|ryP Mmf4OFghcA>? NXvPV5BUTE2VTx?= NEHi[IxKSzVyPUCuNFc4KM7:TR?= NX\1U3JNOjF7MkS1Nlg>
Hepa-1c1c7 NYXNNY9DTnWwY4Tpc44hSXO|YYm= MlrJNlUh|ryP M2C5ZlYhcA>? Mn3iSG1UVw>? MlGzTY5kemWjc3XzJG5z\jJicILveIVqdiCuZY\lcC=> MYSyNFM6OjV2NB?=
COS-7 NYm3bFVlS3m2b4TvfIlkKEG|c3H5 MkXiNVAh|ryP M4\HSWROW09? NEHk[nJKSzVyPEGwJO69VQ>? NUTCV3RIOThyOEiwPVc>
HuH-7 MYnDfZRwfG:6aXOgRZN{[Xl? M1f4T|ExKM7:TR?= NHnkV4dFVVOR MnLQTWM2ODxzMDFOwG0> NH[5UlUyQDB6OEC5Oy=>
OCI-Ly3 NHTjS2NHfW6ldHnvckBCe3OjeR?= NIPBcXkyOCEQvF5CpC=> M3HPRVQhcA>? M{DaOmROW09? MYPJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>? MXSxPFAzPDFzMx?=
A2780 cDDP MWLBdI9xfG:|aYOgRZN{[Xl? MnnZNlQhcA>? NFHPbYxFVVOR NUjxeIhwUW6mdXPld{BieG:ydH;zbZMh[nliaX7obYJqfGmwZzDQWGVPKGSnZ4Lh[IF1cW:w MV2xO|Y5PDBzOB?=
LPS-stimulated RAW264.7 cells MV3GeY5kfGmxbjDBd5NigQ>? M{XCNWROW09? M3rIOmlvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>? MXyxO|QxPzJ5Nx?=
PC12 NILp[2lHfW6ldHnvckBCe3OjeR?= NEjjZnUyODBizszNxsA> NEfkSnMzPCCq NYHVdXFPTE2VTx?= NHHicZJKdmirYnn0d{A3NU:KRFGtJIFv\CCKMl:yMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MUGxO|E2QDR3NB?=
PC3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfhWVRzOjBizszN NGeyeIg1QCCq MlrsSG1UVw>? NVXB[JM2UUN3ME2wMlYh|ryP NXnoVllLOTZ4OE[1N|c>
LP-1 MXHBdI9xfG:|aYOgRZN{[Xl? Mof2N|AxKG6P MmLTNlQhcA>? MmK0SG1UVw>? M4D5eWlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwY4LlZZNqdmdiY3zlZZZm\CCSQWLQJIxmfmWuIHHu[EBz\WS3Y3nu[{BO[2xvMTDwdo91\WmwIHzleoVt NUntSXppOTV7NUi1PFk>
ES6 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6VXlsUUN3ME2wMlAyOzB4IN88US=> MmTmV2FPT0WU
A101D NYCycI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX6dHdKSzVyPUCuNFMzPzlizszN MYjTRW5ITVJ?
OCUB-M MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn30TWM2OD1yLkCzO|M4KM7:TR?= NWL2dZg1W0GQR1XS
LB2518-MEL NGrVT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;zV2t1UUN3ME2wMlA{PzZizszN NXzJ[FduW0GQR1XS
SH-4 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M121WmlEPTB;MD6wOFMyKM7:TR?= M1jFe3NCVkeHUh?=
KNS-42 NHvBXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfuTWM2OD1yLkC0OFQyKM7:TR?= NHTmXIRUSU6JRWK=
DSH1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG4T|hjUUN3ME2wMlA2Ojh7IN88US=> NV63O5hJW0GQR1XS
NTERA-S-cl-D1 NYrZboQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEW3O|Ih|ryP Mo[1V2FPT0WU
D-542MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEW5OVch|ryP NUnjUWNDW0GQR1XS
KS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjWe|FKSzVyPUCuNFY1PThizszN MV7TRW5ITVJ?
BL-41 NXjn[oF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvSZYpKSzVyPUCuNFY6PDdizszN MkfnV2FPT0WU
LXF-289 NVu3b29ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\iTWM2OD1yLkC3NFY3KM7:TR?= MWDTRW5ITVJ?
D-247MG NV6y[29vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEeyNFkh|ryP M2DYRXNCVkeHUh?=
MMAC-SF NYPYSVE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LUOGlEPTB;MD6wO|I3QCEQvF2= MlPKV2FPT0WU
CP66-MEL MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2UHhKSzVyPUCuNFc2KM7:TR?= M{fVSnNCVkeHUh?=
LB771-HNC MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\STWM2OD1yLkC4NFM3KM7:TR?= MUjTRW5ITVJ?
no-10 M4X1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ZZnlbUUN3ME2wMlA5QTB7IN88US=> NUjZRnZwW0GQR1XS
A388 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITCfmhKSzVyPUCuNFkxPjVizszN NV3KWYFSW0GQR1XS
OPM-2 NF;odGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HZRWlEPTB;MD6xNFQ4PCEQvF2= MWDTRW5ITVJ?
OVCAR-4 M{H3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUC5N|gh|ryP NF76WVJUSU6JRWK=
HOP-62 M1zwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\BTWM2OD1yLkGwPVQ6KM7:TR?= NXXmeG1PW0GQR1XS
ML-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3FU2lKSzVyPUCuNVE5ODZizszN NEHVVY5USU6JRWK=
UACC-257 M4DaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIflfYNKSzVyPUCuNVE6OjdizszN MXHTRW5ITVJ?
NEC8 M2PP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLucGtKSzVyPUCuNVE6QTVizszN M3XH[3NCVkeHUh?=
ONS-76 NV30d5hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm3TWM2OD1yLkGyPVM2KM7:TR?= MnrwV2FPT0WU
KE-37 NHPlWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfZ[nhKSzVyPUCuNVMzPzhizszN NVzhOllHW0GQR1XS
HT-144 NX;TT5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fhbmlEPTB;MD6xN|g6PSEQvF2= NUHOOY5PW0GQR1XS
LB2241-RCC NHG0XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12yPGlEPTB;MD6xOFI1PyEQvF2= NXXaWWw4W0GQR1XS
TE-5 NIfMTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFriPXNKSzVyPUCuNVQzPzhizszN MVfTRW5ITVJ?
KINGS-1 NYftZ2oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXIUpR2UUN3ME2wMlE1PzlizszN M4XGbXNCVkeHUh?=
NCI-H69 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLqfGFKSzVyPUCuNVUyPDFizszN NXvOOI5[W0GQR1XS
CAS-1 NFrBOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwOFFKSzVyPUCuNVU1QDJizszN M2rxPXNCVkeHUh?=
D-263MG MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7hcZFKSzVyPUCuNVYxODZizszN NF;XUYNUSU6JRWK=
A253 M3\GS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljpTWM2OD1yLkG2NVI5KM7:TR?= NIT6NZNUSU6JRWK=
PF-382 M2jPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS4TWM2OD1yLkG2O|A3KM7:TR?= NHvoZ2VUSU6JRWK=
CESS NWLjbpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnDbndTUUN3ME2wMlE4ODZizszN MYLTRW5ITVJ?
MZ2-MEL NWLZSXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMUe1OVkh|ryP MmrCV2FPT0WU
HEL NITCcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXDbWJmUUN3ME2wMlE5PTF5IN88US=> M4\YPXNCVkeHUh?=
D-392MG NITNOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPYcJp{UUN3ME2wMlE6OTF3IN88US=> M3T0eHNCVkeHUh?=
SK-LMS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvpfINKSzVyPUCuNVk{ODNizszN M4TQdXNCVkeHUh?=
GI-ME-N M2PyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni0TWM2OD1yLkG5N|A3KM7:TR?= NEPPdotUSU6JRWK=
LB831-BLC Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTITGxFUUN3ME2wMlE6OzRizszN NUf4e45XW0GQR1XS
DU-4475 M17OS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjofI5MUUN3ME2wMlE6PjV6IN88US=> Mln5V2FPT0WU
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljKTWM2OD1yLkKwNFk1KM7:TR?= NGfwUHZUSU6JRWK=
GAK MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMkC1N|Qh|ryP NVPJVXZZW0GQR1XS
EW-1 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULXem04UUN3ME2wMlIyODR5IN88US=> NXHvVJV1W0GQR1XS
LAMA-84 NFrGS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPLTWM2OD1yLkKxPFUyKM7:TR?= NFW1doFUSU6JRWK=
SK-UT-1 NXXm[JpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkKwOFkh|ryP MX\TRW5ITVJ?
VA-ES-BJ M4rjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW3U4NKSzVyPUCuNlIzPTdizszN MlXHV2FPT0WU
ACN NV\5dpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMkK2N|gh|ryP M1LvT3NCVkeHUh?=
SK-PN-DW M{P5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT2TWM2OD1yLkKzNVkh|ryP M3q2d3NCVkeHUh?=
HD-MY-Z Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMkOzNFMh|ryP NXfifoY1W0GQR1XS
LB373-MEL-D MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMkSxPVgh|ryP NGjCfGFUSU6JRWK=
COLO-829 NX3LeohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMkSyOVch|ryP MXzTRW5ITVJ?
ES8 M{e3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDPGlEPTB;MD6yOFc3OyEQvF2= NXTzS5d[W0GQR1XS
RXF393 M2f1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4NIFKSzVyPUCuNlUxOTVizszN NVrDVo5HW0GQR1XS
TK10 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXybZRKSzVyPUCuNlU1OzVizszN M{PqfXNCVkeHUh?=
LOUCY Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMkW0OVYh|ryP M{jkPHNCVkeHUh?=
MZ7-mel M{HLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjTdHZKSzVyPUCuNlY{PzRizszN NWf2XW1{W0GQR1XS
CP67-MEL NVTZVHRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMk[3N{DPxE1? MWXTRW5ITVJ?
C2BBe1 M{H2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETuNFVKSzVyPUCuNlc6ODdizszN NFfIVFBUSU6JRWK=
K052 NHPqdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vDcmlEPTB;MD6yPFk6KM7:TR?= Mn:2V2FPT0WU
MOLT-16 M2XO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMkm1NlQh|ryP NEL2e2RUSU6JRWK=
KNS-81-FD M3Tm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwM{CzNlMh|ryP NXG2UGZMW0GQR1XS
CMK MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwM{GxNkDPxE1? NUTQUZB7W0GQR1XS
LAN-6 NX3K[GhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnt[mRYUUN3ME2wMlMyOyEQvF2= MVfTRW5ITVJ?
KLE M{X4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fxV2lEPTB;MD6zNVMxPiEQvF2= MVjTRW5ITVJ?
NCCIT NYjoSWJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO4TWM2OD1yLkOxO|g{KM7:TR?= MYXTRW5ITVJ?
HH MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwM{K4PVch|ryP MnvCV2FPT0WU
TE-8 NIPGUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXIO4NKSzVyPUCuN|QzPzlizszN NVnXd4N5W0GQR1XS
GDM-1 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rwemlEPTB;MD6zOVExPCEQvF2= MmXqV2FPT0WU
NCI-H747 M3vTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn4OW9KSzVyPUCuN|cyODNizszN MkDDV2FPT0WU
NCI-H1092 NUD2WlA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH31cW1KSzVyPUCuN|g5PDRizszN NFP1VppUSU6JRWK=
8-MG-BA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjvbFhSUUN3ME2wMlM6QDN5IN88US=> M4HRVHNCVkeHUh?=
NB17 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X1RmlEPTB;MD60Nlk4KM7:TR?= NEf0PWRUSU6JRWK=
LC4-1 NGrCTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwNEO2NFch|ryP MmPsV2FPT0WU
TE-1 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwNEWxNVkh|ryP NVHPbI1zW0GQR1XS
KALS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DXSmlEPTB;MD60OlU5PCEQvF2= NHLFNndUSU6JRWK=
CCRF-CEM MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETTcohKSzVyPUCuOFc3PzRizszN MmXnV2FPT0WU
OS-RC-2 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TNUGlEPTB;MD60O|k4OiEQvF2= MmDxV2FPT0WU
A704 NU\Ee5RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXQTWM2OD1yLkS4OlkzKM7:TR?= M1j2SnNCVkeHUh?=
BB49-HNC MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnOTWM2OD1yLkS5NFk3KM7:TR?= NIj6O5BUSU6JRWK=
EVSA-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\RNoRKSzVyPUCuOFk6OTFizszN NHOwOllUSU6JRWK=
Mo-T NGPxR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2flJKSzVyPUCuOVE4PjJizszN MWfTRW5ITVJ?
MONO-MAC-6 NELiOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nDcmlEPTB;MD61N|YyOSEQvF2= NXv1O4lnW0GQR1XS
BB65-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XzcWlEPTB;MD61OlgyOSEQvF2= NVvUepd2W0GQR1XS
NCI-H1882 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwNUmwN|Yh|ryP MX7TRW5ITVJ?
TE-9 M2W4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwNkGwN|Mh|ryP MWXTRW5ITVJ?
NCI-H2126 NUTVOHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwNkK2Olkh|ryP MU\TRW5ITVJ?
SF268 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrmbZBYUUN3ME2wMlY2PjRzIN88US=> NVq2SINXW0GQR1XS
SW872 M1u3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNkW3Nlkh|ryP Ml3vV2FPT0WU
LS-513 NH7FenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzV5lnUUN3ME2wMlY3PzVzIN88US=> NVryTVd3W0GQR1XS
NCI-H1355 M1ToRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3VXYpWUUN3ME2wMlY5PjF7IN88US=> MYrTRW5ITVJ?
BL-70 NWPNT4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:xTWM2OD1yLk[5N|g5KM7:TR?= M1izbnNCVkeHUh?=
NCI-SNU-5 M2TvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNkm1OFUh|ryP NXLlOXY4W0GQR1XS
SNU-C2B MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTrV5VxUUN3ME2wMlcxPzN7IN88US=> NXL3NmV7W0GQR1XS
GB-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrPTWM2OD1yLkeyNVI1KM7:TR?= M4LJbXNCVkeHUh?=
CTB-1 M2DHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDjTWM2OD1yLke3PVU2KM7:TR?= Mmq4V2FPT0WU
Becker MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v6PGlEPTB;MD63PVYzOSEQvF2= MX7TRW5ITVJ?
KM12 NH\jVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwOEW0OlYh|ryP NXS0T5VlW0GQR1XS
ES7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXUb5F1UUN3ME2wMlg6PjVizszN M3zndHNCVkeHUh?=
COLO-684 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;5TWM2OD1yLkmwOlU5KM7:TR?= NHLvUlNUSU6JRWK=
HCC2998 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwOUO4OVQh|ryP MnL0V2FPT0WU
TE-10 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPzTWM2OD1yLkm2OFMh|ryP NYT4e|lZW0GQR1XS
SF126 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILrb4NKSzVyPUCuPVg6PzFizszN NWXBUG83W0GQR1XS
EKVX MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPUS29KSzVyPUGuNFM1PDJizszN MlTBV2FPT0WU
KARPAS-45 NV\YO21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn5XpViUUN3ME2xMlA1ODF4IN88US=> NFvCOmJUSU6JRWK=
KGN NWP5dXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT3TWM2OD1zLkC1NFQ2KM7:TR?= NEGwfVRUSU6JRWK=
ES1 NUfNd3lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1zLkC3PVIyKM7:TR?= NHfP[oFUSU6JRWK=
L-540 NWDmS41TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrDToN7UUN3ME2xMlEyQDN7IN88US=> MV7TRW5ITVJ?
KURAMOCHI NVu3N2ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjUfZJxUUN3ME2xMlEzOzd2IN88US=> M36zZnNCVkeHUh?=
LU-65 NXfWTJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnBR4hYUUN3ME2xMlEzPzV|IN88US=> M{PuS3NCVkeHUh?=
MFH-ino NH3EO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDyTWM2OD1zLkG3OVAyKM7:TR?= MXXTRW5ITVJ?
NCI-H23 NWLPTlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3UZllIUUN3ME2xMlIxPDFizszN NV7XTFJlW0GQR1XS
IA-LM MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TCN2lEPTB;MT6yOFEyPiEQvF2= MXnTRW5ITVJ?
PSN1 M1nYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe3dogxUUN3ME2xMlI4ODF4IN88US=> MlrxV2FPT0WU
NCI-H719 M4DrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLOOFVKSzVyPUGuNlc1OTFizszN M2XnZnNCVkeHUh?=
SW684 NV:zOFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljTTWM2OD1zLkK4OlU6KM7:TR?= M4fZe3NCVkeHUh?=
HCE-4 M1;BOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;r[mlEPTB;MT6zNFIzOSEQvF2= MXHTRW5ITVJ?
EW-16 M4rubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37tcWlEPTB;MT6zNVM1PyEQvF2= MmK4V2FPT0WU
NCI-H128 M{fFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfyTWM2OD1zLkO1PFE1KM7:TR?= NXLTR3pyW0GQR1XS
HC-1 M1TBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0TWM2OD1zLkO4NVch|ryP NGr6c4JUSU6JRWK=
IST-MES1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXSY9KSzVyPUGuOFAzODhizszN MYXTRW5ITVJ?
Raji M4jM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF33VIhKSzVyPUGuOFE5PSEQvF2= M3LVOHNCVkeHUh?=
DMS-114 M2XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13odGlEPTB;MT60OFU{QSEQvF2= NFS0SnNUSU6JRWK=
GI-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TQSGlEPTB;MT60O|E{OSEQvF2= NFXm[ppUSU6JRWK=
NCI-H2081 NYnHdVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7IdnVKSzVyPUGuOVUyQTZizszN MmDEV2FPT0WU
LC-1F MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLTphKUUN3ME2xMlU2OTl6IN88US=> MWXTRW5ITVJ?
NCI-H2227 NWm0bZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\nTWM2OD1zLk[xOVYyKM7:TR?= M{LjU3NCVkeHUh?=
D-502MG MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO3e2hKSzVyPUGuOlczOTFizszN M3PLOHNCVkeHUh?=
NCI-H2141 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli3TWM2OD1zLk[3N|E4KM7:TR?= NWD1OJRYW0GQR1XS
LS-411N Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTUTWM2OD1zLk[5PFA4KM7:TR?= MoHHV2FPT0WU
SU-DHL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2TWM2OD1zLkexNlgyKM7:TR?= M2DSe3NCVkeHUh?=
BB30-HNC Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnEVHJHUUN3ME2xMlczPjh3IN88US=> M2TWNnNCVkeHUh?=
TE-15 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TFSGlEPTB;MT65NlM4OyEQvF2= MVvTRW5ITVJ?
JVM-3 NF;1SXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;hTWM2OD1zLkmzPVA1KM7:TR?= MkTIV2FPT0WU
IST-SL2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DZcGlEPTB;Mj6wNVI2OiEQvF2= M3vtd3NCVkeHUh?=
EW-18 M4H5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m0XmlEPTB;Mj6wNlM{PyEQvF2= MUDTRW5ITVJ?
DJM-1 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwMEK1OVIh|ryP MWHTRW5ITVJ?
no-11 M3LBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WwWWlEPTB;Mj6wN|ExPCEQvF2= MULTRW5ITVJ?
QIMR-WIL NGXsWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwMU[3OlIh|ryP NXfUU4p6W0GQR1XS
MC-CAR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLqU3dKSzVyPUKuNlI6PSEQvF2= Mkj5V2FPT0WU
KM-H2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwMkmwOFMh|ryP MnG1V2FPT0WU
ECC12 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PdWlEPTB;Mj6zO|k1KM7:TR?= Mn3MV2FPT0WU
HCE-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzmN5BRUUN3ME2yMlQ1QDh|IN88US=> MofjV2FPT0WU
MFM-223 M4C0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwNUC4O|Eh|ryP M3jpeHNCVkeHUh?=
SW982 NVm4OFE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXTcnJyUUN3ME2yMlUyPDhizszN NWnMRphWW0GQR1XS
KG-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwOEi3PVEh|ryP NVnjVnpKW0GQR1XS
ES4 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv6WGRwUUN3ME2zMlA3OTFzIN88US=> M1XBV3NCVkeHUh?=
SCC-3 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr2TWM2OD1|LkGwPFQ5KM7:TR?= NXPXUVRiW0GQR1XS
RH-1 NGHrfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPtTnRKSzVyPUOuN|g4PDhizszN NGS5b3pUSU6JRWK=
NCI-H748 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC2Sm4zUUN3ME2zMlQ1OjZ4IN88US=> MmrxV2FPT0WU
HCC2218 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXn[WU5UUN3ME2zMlQ3QTN5IN88US=> NIPmPFJUSU6JRWK=
MEG-01 M4LIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPQeHVFUUN3ME2zMlU6PjhizszN M{\JW3NCVkeHUh?=
NB12 NUnOcFlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPie4FKSzVyPUOuOVk5QDhizszN MVHTRW5ITVJ?
SNB75 MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNwNkCxNFMh|ryP MUfTRW5ITVJ?
KMS-12-PE NXzLe25KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT6coVKSzVyPUOuOlc4OjNizszN NYDn[GhtW0GQR1XS
SKM-1 NGG0fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrZ[5VKSzVyPUOuO|E{PzZizszN M2mw[XNCVkeHUh?=
COLO-320-HSR NYPJXllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfu[4F2UUN3ME2zMlc2PjN2IN88US=> NU\QfmI6W0GQR1XS
NKM-1 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwN{ezO|gh|ryP MV\TRW5ITVJ?
TE-6 NFz1ZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;XXIdjUUN3ME2zMlk1PTZzIN88US=> NXLJZ4xbW0GQR1XS
D-336MG M3P0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HXbmlEPTB;ND6wNVE3PiEQvF2= MmTLV2FPT0WU
NCI-H1650 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qxXGlEPTB;ND6xOVc6PyEQvF2= NID4bJVUSU6JRWK=
ES3 NGPoOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Gc5lKSzVyPUSuN|I5OjRizszN Moi3V2FPT0WU
YT M3zYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHsTWM2OD12LkO1OFI1KM7:TR?= NF;rN21USU6JRWK=
ES5 NUnFT3BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sbmlEPTB;ND60NFI2PSEQvF2= M2n4d3NCVkeHUh?=
LB647-SCLC MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{juR2lEPTB;ND61OlMxQCEQvF2= M33lSHNCVkeHUh?=
HAL-01 NVrSO5dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXGO2VxUUN3ME20MlU4ODN2IN88US=> MWDTRW5ITVJ?
LP-1 NU\yVZRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HMTGlEPTB;ND63NlM4OSEQvF2= MlWyV2FPT0WU
BC-1 NIfON3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fSZWlEPTB;NT6wNFQ1PyEQvF2= NFnsTllUSU6JRWK=
EB-3 NG\OXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwMEOwOFEh|ryP NYjKUJB5W0GQR1XS
GT3TKB MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4juUGlEPTB;NT6xO|Y3OiEQvF2= NFfh[2FUSU6JRWK=
NCI-H209 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[0bmlEPTB;NT6xPVM2OiEQvF2= MlLxV2FPT0WU
BT-474 NWjRS5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Oy[WlEPTB;NT6yN|ExOiEQvF2= M1HlU3NCVkeHUh?=
RKO NWDvR4dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP5TWM2OD13LkKzOFIzKM7:TR?= NIDibFFUSU6JRWK=
SIMA NFTVPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3kWGhnUUN3ME21MlMxPzZ3IN88US=> MU\TRW5ITVJ?
RL M4r6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXZTWM2OD13LkO3OVQyKM7:TR?= M3nJ[XNCVkeHUh?=
GCIY M1fMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHTmlEPTB;NT60O|I{PiEQvF2= MnqyV2FPT0WU
Calu-6 NGfQNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiwd3J3UUN3ME21MlYzOiEQvF2= NYLWfGVpW0GQR1XS
ALL-PO M3riS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zCU2lEPTB;NT62N|c6PSEQvF2= NES1S2dUSU6JRWK=
ARH-77 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ITWM2OD13Lk[3NFg4KM7:TR?= NUDHfGxGW0GQR1XS
A4-Fuk NUDGU2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD14LkC4NVE5KM7:TR?= MXLTRW5ITVJ?
NCI-H1581 NUL0e|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nKTWlEPTB;Nj6yN|g1QSEQvF2= M13oUnNCVkeHUh?=
HUTU-80 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZwM{[4PVch|ryP NF\NfVZUSU6JRWK=
TGW Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly3TWM2OD14LkS1OVk{KM7:TR?= MVjTRW5ITVJ?
SK-N-FI M4C5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT0e5RKSzVyPU[uOFU5PTRizszN M3fpU3NCVkeHUh?=
U-266 NYLhWlJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLnTWM2OD14LkWxPVI3KM7:TR?= NFK4VnVUSU6JRWK=
EM-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwNkewPVkh|ryP NWqxVVZzW0GQR1XS
NMC-G1 M1\F[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFRm02UUN3ME22MlcyQDl3IN88US=> NF7JTWRUSU6JRWK=
KASUMI-1 M4r6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKeo5KSzVyPU[uPFQ4QDdizszN M2DS[3NCVkeHUh?=
NALM-6 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n4OGlEPTB;Nj64Olc2PCEQvF2= MnrQV2FPT0WU
OCI-AML2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTdwMECzNlYh|ryP MkmxV2FPT0WU
SHP-77 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTdwMkK0N{DPxE1? M1;wbHNCVkeHUh?=
NOMO-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m4TWlEPTB;Nz6yOFI2PCEQvF2= MlHIV2FPT0WU
SK-N-DZ NY\LPWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnezTWM2OD15LkexNFg6KM7:TR?= NH73VFFUSU6JRWK=
LB1047-RCC M4TQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWxdlBGUUN3ME23MlczOjNzIN88US=> MmjYV2FPT0WU
MZ1-PC Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qVJlKSzVyPUeuPFY2PThizszN NIjR[oJUSU6JRWK=
NB10 M1vhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXmdo9CUUN3ME23Mlk6PTV4IN88US=> NWHlRmE5W0GQR1XS
RL95-2 NXjUR5JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHDNIRKSzVyPUiuNVA5PDJizszN MoLOV2FPT0WU
OMC-1 M{n6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRThwNUKxPVEh|ryP M1LyR3NCVkeHUh?=
D-283MED MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwOUG3NVkh|ryP NHXMeJBUSU6JRWK=
MC116 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS1WpBKSzVyPUiuPVc6PCEQvF2= MYnTRW5ITVJ?
SJSA-1 M{PhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrjTWM2OD17LkC5NFkyKM7:TR?= NEjH[YxUSU6JRWK=
JiyoyeP-2003 NEflRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli3TWM2OD17LkK5N|E4KM7:TR?= M1XkU3NCVkeHUh?=
IST-MEL1 NHuxdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTBRXpKSzVyPUmuO|QyQThizszN M{\RfnNCVkeHUh?=
CTV-1 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFyLkC5O|kh|ryP NFXGfWpUSU6JRWK=
NH-12 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFyLkK0N|Mh|ryP MoT5V2FPT0WU
CA46 NV3qfVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PCb2lEPTB;MUCuN|YyKM7:TR?= MXrTRW5ITVJ?
NCI-SNU-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf6dVNKSzVyPUGwMlQ6PjlizszN NYOzRmZ4W0GQR1XS
SCLC-21H MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvrb|E3UUN3ME2xNE43PTl4IN88US=> NF7DZVZUSU6JRWK=
EC-GI-10 NIjxeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe3SI1KSzVyPUGwMlcxOzFizszN Mo\DV2FPT0WU
SR NFTRXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrP[25KSzVyPUGxMlAyQDVizszN Mo\YV2FPT0WU
NCI-H1648 NILqWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHRO4c4UUN3ME2xNU4xQTZ3IN88US=> MnjvV2FPT0WU
TGBC1TKB M1nlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TMXGlEPTB;MUGuOFExOiEQvF2= NGD2[YxUSU6JRWK=
EW-11 NEDIPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[yeXZKSzVyPUGxMlUyQDZizszN NVfQXVRHW0GQR1XS
SK-MM-2 NHfUR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPKTWM2OD1zMT64NFYyKM7:TR?= NWT6SYdQW0GQR1XS
NCI-H524 NY\nR|hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFzLkm4NlIh|ryP MX\TRW5ITVJ?
NOS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7jTWM2OD1zMj6wN|Q2KM7:TR?= MlzHV2FPT0WU
AM-38 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF{LkW2N|Mh|ryP NUXTO297W0GQR1XS
A498 NUSyfWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrhTWM2OD1zMj63NFY6KM7:TR?= MWfTRW5ITVJ?
KARPAS-422 M{XZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7vS2hPUUN3ME2xNk44PDl4IN88US=> MVrTRW5ITVJ?
LU-139 M4mxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHhfZB[UUN3ME2xNk46ODJ4IN88US=> MUfTRW5ITVJ?
COR-L88 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzkZZlKSzVyPUGyMlk{QDJizszN NXX2fWdJW0GQR1XS
K5 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{Lkm0OlIh|ryP NXrIZYtpW0GQR1XS
NB13 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H5UmlEPTB;MUKuPVc5OyEQvF2= NFLxZXlUSU6JRWK=
MRK-nu-1 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzT[5JKSzVyPUGzMlE6PSEQvF2= NVu4W4N7W0GQR1XS
MHH-NB-11 NHXUVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TvN2lEPTB;MUOuNlkxOiEQvF2= NEnKfohUSU6JRWK=
KU812 M{K1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvjTWM2OD1zMz62NVI1KM7:TR?= MUjTRW5ITVJ?
TE-12 NIXzRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrEb2FKSzVyPUGzMlY6QTRizszN MnP5V2FPT0WU
NCI-N87 M1K3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxcWNKSzVyPUGzMlc{PiEQvF2= Ml;VV2FPT0WU
EB2 NUPaNHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDFd|hKSzVyPUGzMlg2ODVizszN NXe4VZNpW0GQR1XS
DB NHXzWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTncpFOUUN3ME2xN{46QDh3IN88US=> MWfTRW5ITVJ?
697 NHj2RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GwRWlEPTB;MUSuOFUyOSEQvF2= MX7TRW5ITVJ?
MSTO-211H NGXJVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XHO2lEPTB;MUSuO|Q1QCEQvF2= MXnTRW5ITVJ?
JVM-2 M13E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljQTWM2OD1zND63O|M2KM7:TR?= MXrTRW5ITVJ?
COLO-824 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LZXmlEPTB;MUSuO|k6PCEQvF2= M1Pn[3NCVkeHUh?=
BC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnHN3dDUUN3ME2xOU4{QThizszN NXv2[3dyW0GQR1XS
BOKU NITlVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDubohKSzVyPUG1Mlk3ODhizszN MWHTRW5ITVJ?
GOTO M1np[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;heGlEPTB;MU[uPVYyPyEQvF2= NIK0bJVUSU6JRWK=
HCC2157 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX1b|RUUUN3ME2xO{41PzV3IN88US=> NYDDR3pCW0GQR1XS
LS-1034 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\JTWM2OD1zNz62PFE5KM7:TR?= MkTIV2FPT0WU
CAL-148 NITjbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7mSpdNUUN3ME2xO{46Pzl4IN88US=> NHH0[2dUSU6JRWK=
MOLT-4 NUP0UG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy0VJpSUUN3ME2xPE45OjB6IN88US=> M3;rfHNCVkeHUh?=
Daudi NGfoN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHaTWM2OD1zOD65NlMyKM7:TR?= MlnsV2FPT0WU
J-RT3-T3-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF7LkSwOlYh|ryP MlvnV2FPT0WU
KMOE-2 NEj1[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO0WpBnUUN3ME2xPU43PDh{IN88US=> MUDTRW5ITVJ?
HL-60 NXnHeoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLOTWM2OD1{MD6xPVY2KM7:TR?= NETVVmtUSU6JRWK=
P31-FUJ NW[2cVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJyLkS3OVMh|ryP MW\TRW5ITVJ?
IM-9 NU\keXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDsWHg6UUN3ME2yNE43OjJ2IN88US=> NUHpU5cyW0GQR1XS
HDLM-2 M17QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofmTWM2OD1{MD64PFIyKM7:TR?= MUTTRW5ITVJ?
NCI-H1304 NVqyb2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nYSWlEPTB;MkGuNFMyOSEQvF2= MUXTRW5ITVJ?
NCI-H345 M3P2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyxZWtKSzVyPUKxMlA3PDNizszN NH:0TJhUSU6JRWK=
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD1{MT6zOlAzKM7:TR?= MWPTRW5ITVJ?
GR-ST MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\qTWM2OD1{MT60NVch|ryP Mn;nV2FPT0WU
CHP-126 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvUTWM2OD1{MT62NVgyKM7:TR?= MnPpV2FPT0WU
EHEB M1:1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLQU3BKSzVyPUKxMlY4OzFizszN NFHyW3NUSU6JRWK=
CPC-N NYfiXHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W3NWlEPTB;MkSuNFIxOSEQvF2= NHvZV2xUSU6JRWK=
NB1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M322bWlEPTB;MkSuOlk{QSEQvF2= M3jpOXNCVkeHUh?=
LS-123 M1zuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZR2lEPTB;MkSuPVAyOiEQvF2= NEfkVVhUSU6JRWK=
ST486 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXkXIFKSzVyPUK1MlEyOTNizszN NF;sb5lUSU6JRWK=
NCI-H1963 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXzTWM2OD1{Nj6wOlI{KM7:TR?= M3TaN3NCVkeHUh?=
U-87-MG NGPkT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0ZWlEPTB;Mk[uO|Y1PCEQvF2= M{DObXNCVkeHUh?=
COR-L279 NWixboN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXkR3ZKSzVyPUK2Mlc6OjJizszN MlTnV2FPT0WU
LU-165 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XXSmlEPTB;MkiuNFg3OSEQvF2= NVLlW5VuW0GQR1XS
COLO-800 NX7kXnJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ6LkK5OVYh|ryP NGS3[GFUSU6JRWK=
ETK-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i4W2lEPTB;MkiuN|Q1PiEQvF2= NVX4[4pLW0GQR1XS
LNCaP-Clone-FGC MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPkSYNKSzVyPUK5MlkzQDFizszN MX3TRW5ITVJ?
SIG-M5 M{ix[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnyN|NKSzVyPUOwMlc6PTJizszN NXK0PJl4W0GQR1XS
NB6 NGrSb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wVFRKSzVyPUOwMlk2ODNizszN NYO5UWRQW0GQR1XS
NCI-H2107 M2jRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSySXlKSzVyPUOxMlI{OzhizszN MYPTRW5ITVJ?
SNU-C1 M4\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnoN5ZSUUN3ME2zNU4{OTJ4IN88US=> NVi1OFR7W0GQR1XS
JAR NV75c3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfjOm9oUUN3ME2zNU4{Pzl7IN88US=> MXnTRW5ITVJ?
L-363 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17EZWlEPTB;M{KuNlE1PCEQvF2= M1vCZnNCVkeHUh?=
EW-24 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjtNG9KSzVyPUOyMlM1PzRizszN MYXTRW5ITVJ?
NB69 NVTjRZFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wcWxKSzVyPUOzMlY1PTRizszN NFjz[IxUSU6JRWK=
EW-13 NVS2NYJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN|Lki5Olkh|ryP M4LkU3NCVkeHUh?=
Ramos-2G6-4C10 M{j2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzoTWM2OD1|ND6yPVk{KM7:TR?= NHWwVG9USU6JRWK=
TE-11 NGm5RmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN2LkS4NlIh|ryP NEjsWnlUSU6JRWK=
L-428 NY[yfFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLDRYJbUUN3ME2zOE44PTN4IN88US=> MXXTRW5ITVJ?
KP-N-YN NVq0TWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPpe|B4UUN3ME2zOE46ODV5IN88US=> NHPiU4lUSU6JRWK=
CGTH-W-1 M3vRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN4LkmwOFgh|ryP MVzTRW5ITVJ?
K-562 NFrZ[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTJN5J5UUN3ME2zO{4xQDZ2IN88US=> MVnTRW5ITVJ?
NCI-H1299 M4TMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN6LkG2NFMh|ryP NXHHSHlJW0GQR1XS
RCC10RGB M{\hWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDTWM2OD1|OD6yNFg{KM7:TR?= MXfTRW5ITVJ?
NCI-SNU-16 NEPoSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP2[JpKSzVyPUO4MlU3PTNizszN MoDtV2FPT0WU
LC-2-ad MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vTGlEPTB;M{muOFM{PyEQvF2= M2\Xb3NCVkeHUh?=
MHH-PREB-1 NGfFNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN7LkezPFgh|ryP MnTmV2FPT0WU
NCI-H64 M2LVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD12MD6wPVQ5KM7:TR?= MlPRV2FPT0WU
LB996-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;aZm5KSzVyPUSwMlg4OTZizszN MU\TRW5ITVJ?
DEL MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j3[GlEPTB;NEGuOFQxPSEQvF2= MkjNV2FPT0WU
MLMA M4\5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCTpBKSzVyPUSxMlc2QTVizszN M1\RUXNCVkeHUh?=
SBC-1 NWCxeZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK1WFhKSzVyPUSyMlE5ODZizszN MkjJV2FPT0WU
MPP-89 M1j3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO3TWM2OD12Mj61PFc2KM7:TR?= MlraV2FPT0WU
MV-4-11 NHfUUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnZXWJKSzVyPUSyMlkxPjdizszN M4rndHNCVkeHUh?=
EoL-1- NUW4dVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zKT2lEPTB;NESuNVU3QCEQvF2= NUjzUmtYW0GQR1XS
CW-2 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmryTWM2OD12ND64N|QzKM7:TR?= NEfTXGJUSU6JRWK=
HT MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:0OmpsUUN3ME20OU44ODB5IN88US=> MVLTRW5ITVJ?
SW954 M2PhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTsTWM2OD12Nz60NVI5KM7:TR?= MVPTRW5ITVJ?
A3-KAW NHzEe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXXN5RVUUN3ME20PU45ODZzIN88US=> NWPm[Y5HW0GQR1XS
TC-YIK M4\2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fZVmlEPTB;NUCuNFM3OyEQvF2= NF7vbXdUSU6JRWK=
SW962 NEfabnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\GWXk{UUN3ME21OE45OzV5IN88US=> M33rcXNCVkeHUh?=
KP-N-RT-BM-1 NVXIN|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDtTWM2OD13Nj62OlM5KM7:TR?= NVjJUFJtW0GQR1XS
NCI-H1395 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X2ZmlEPTB;NUiuPFE4OiEQvF2= NWmycHNtW0GQR1XS
RPMI-8402 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDQTWM2OD13OD65OVI3KM7:TR?= NFH5bJVUSU6JRWK=
SCH MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Pxc2lEPTB;NkCuPVY{QCEQvF2= NWK2Z4RLW0GQR1XS
NCI-H2196 NX\UfGdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTZzLkKzNUDPxE1? M1nvdXNCVkeHUh?=
LOXIMVI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC1T3JIUUN3ME22NU45OjZ4IN88US=> M1rjR3NCVkeHUh?=
TGBC24TKB MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHVbHBTUUN3ME22Nk4yPDlzIN88US=> MWTTRW5ITVJ?
SK-MEL-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;EfmlEPTB;NkOuPVg6OiEQvF2= M2e1WXNCVkeHUh?=
U-698-M NI\NSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTZ6LkW2PFch|ryP MUDTRW5ITVJ?
NCI-H1522 NIC0SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j3cmlEPTB;NkmuNFA1PyEQvF2= NVr5b4MzW0GQR1XS
UACC-812 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjSXXJqUUN3ME22PU42OjB7IN88US=> MWPTRW5ITVJ?
MHH-CALL-2 NF35UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdyLkC2JO69VQ>? MUnTRW5ITVJ?
NB5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofvTWM2OD15MD6zOFY5KM7:TR?= M1rtUHNCVkeHUh?=
KARPAS-299 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;pTWM2OD15MD60OFQ4KM7:TR?= MVvTRW5ITVJ?
NCI-H1694 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\aSXhQUUN3ME23NU4xOzJizszN MYPTRW5ITVJ?
NCI-H82 NUPVXno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTdzLkm1NFch|ryP M1fKXHNCVkeHUh?=
SCC-15 NXTwS2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLyfnNoUUN3ME23Nk4{PCEQvF2= NVjXbFBmW0GQR1XS
NCI-H1436 NELQenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLyTWM2OD15Mj63OFU3KM7:TR?= NIL2e5JUSU6JRWK=
ATN-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBdHdKSzVyPUe0MlUxPSEQvF2= MnW3V2FPT0WU
RPMI-8866 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;6TYhKSzVyPUe0Mlc2ODlizszN MYLTRW5ITVJ?
HCC1599 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTOTmdKSzVyPUe0Mlg4OzJizszN MV;TRW5ITVJ?
NCI-H1155 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xcZdKSzVyPUe0Mlk{PjdizszN NYfMelExW0GQR1XS
DOHH-2 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTd2Lkm1NVQh|ryP Mme5V2FPT0WU
SK-NEP-1 NIDreIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK0W4JuUUN3ME23OU4xPzV2IN88US=> MXvTRW5ITVJ?
HCC1187 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd5Lk[xNlIh|ryP M1vtUnNCVkeHUh?=
NCI-H322M NFztdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rnfGlEPTB;N{iuN|cxQSEQvF2= MVfTRW5ITVJ?
NCI-H526 NUjwR5g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD15OD61PFc4KM7:TR?= MYTTRW5ITVJ?
NCI-H2171 M{fH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzvXG1KSzVyPUe5MlQyOzZizszN M3vT[3NCVkeHUh?=
COLO-668 NVHDU|diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD5PIFKSzVyPUixMlU5QDRizszN NIT6bJBUSU6JRWK=
RS4-11 NFzPNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7mUm9KSzVyPUiyMlI2ODVizszN MoXUV2FPT0WU
NCI-H716 NWjRUFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fWRmlEPTB;OEKuPVA4PSEQvF2= MYrTRW5ITVJ?
LU-134-A MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTh|LkGzOVEh|ryP NVrTWGtbW0GQR1XS
RPMI-8226 M3i4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnNVotqUUN3ME24OE4zOTB5IN88US=> MnTQV2FPT0WU
KY821 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnjR|FKSzVyPUmxMlY2PTFizszN NHLDdIRUSU6JRWK=
ECC4 M1HyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfLSVBpUUN3ME25N{45OjZ7IN88US=> NU\VPYpPW0GQR1XS
EW-3 NXfadYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\wPWZKSzVyPUm0MlkxQDFizszN MXLTRW5ITVJ?
NB7 NHL1cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXafGgyUUN3ME25OU44Pzh4IN88US=> M2\vbnNCVkeHUh?=
NCI-H720 MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrISm5KSzVyPUm4MlQxPjFizszN NIP6eHFUSU6JRWK=
NCI-H446 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTl7Lke1PFgh|ryP NIe4[JlUSU6JRWK=
NCI-H889 NFLjR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T0[mlEPTB;MUC0MlI1OiEQvF2= MXjTRW5ITVJ?
EW-22 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFyNj6xPUDPxE1? MnfkV2FPT0WU
BV-173 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fCPWlEPTB;MUC4MlczQCEQvF2= NIezUG5USU6JRWK=
WSU-NHL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWz[WJ4UUN3ME2xNFkvPjdzIN88US=> MU\TRW5ITVJ?
MN-60 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDseHozUUN3ME2xNFkvPjlizszN NV\VbHVtW0GQR1XS
DG-75 M3vW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;GUHR7UUN3ME2xNVMvOzV{IN88US=> M4nDVXNCVkeHUh?=
DMS-79 M2Kw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOxTWM2OD1zMUeuN|gzKM7:TR?= NUXkXGVKW0GQR1XS
SK-MEL-1 NIS3VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7lb4JEUUN3ME2xNVgvODB7IN88US=> MW\TRW5ITVJ?
DMS-153 NGPxS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;kdlVKSzVyPUGyNU44PDVizszN NVzjdZVxW0GQR1XS
NCI-H510A NUOyN2NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q0OmlEPTB;MUK3MlMzKM7:TR?= Ml;EV2FPT0WU
BE-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\TTWM2OD1zM{SuNFQ1KM7:TR?= MXLTRW5ITVJ?
KP-N-YS NYL0cHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfq[Y5KSzVyPUGzPU44OzZizszN M4fCO3NCVkeHUh?=
SUP-T1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHQdJBxUUN3ME2xOFMvPzB6IN88US=> NH7oTIdUSU6JRWK=
EW-12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPyU|dIUUN3ME2xOFQvPjl7IN88US=> MonnV2FPT0WU
NB14 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7CTWM2OD1zNEeuNFgzKM7:TR?= NV7Vb2trW0GQR1XS
MDA-MB-134-VI M3jCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWyR|dMUUN3ME2xOFgvOjZ6IN88US=> MWrTRW5ITVJ?
NCI-H1770 NVT3RpR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG4TWM2OD1zNU[uNlc6KM7:TR?= NH3pfopUSU6JRWK=
TUR NIi2VG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XpeWlEPTB;MU[3Mlg4KM7:TR?= NWPsb3hnW0GQR1XS
NCI-H1417 M2nGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDO[pViUUN3ME2xPFAvOzNzIN88US=> M4H6dHNCVkeHUh?=
IMR-5 M3T1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HCV2lEPTB;MUixMlU4OSEQvF2= Ml;TV2FPT0WU
NCI-H226 M2q0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1UGlEPTB;MUi4Mlg3PiEQvF2= NXXGUoNDW0GQR1XS
NCI-H187 NVWwfmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnSVYNKSzVyPUG5NE4xPjRizszN M2Cz[XNCVkeHUh?=
SF539 M4Pne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTQ[4tXUUN3ME2xPVIvPzJ6IN88US=> MoPoV2FPT0WU
TALL-1 NWfYb3BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjmTWM2OD1zOUiuN|A1KM7:TR?= NWrHdWg2W0GQR1XS
TE-441-T Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HVbWlEPTB;MUm5Mlc{QSEQvF2= NUjjUVhIW0GQR1XS
REH M{jqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnTTWM2OD1{M{[uOlI3KM7:TR?= MnnTV2FPT0WU
MS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ|OT6xNlEh|ryP NWXtWGFmW0GQR1XS
THP-1 M1Tob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxW281UUN3ME2yOlQvPzN6IN88US=> MluwV2FPT0WU
NCI-H1838 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO3TWM2OD1{N{GuOFU3KM7:TR?= M3njZnNCVkeHUh?=
P30-OHK M3r6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ6Mz64OFch|ryP M{S0VnNCVkeHUh?=
C8166 NFK5d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CzNWlEPTB;M{S1MlM{QCEQvF2= NIX3WZNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

細胞アッセイ:

[3]

細胞株 KIM-2, HC11, and ES
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 24, and 48 hours
実験の流れ

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

動物実験:

[7]

動物モデル Male mdx (C57BL/10ScSn DMD mdx) mice
製剤 Dissolved in DMSO, and diluted in PBS
投薬量 ~10 μg/kg/day
投与方法 Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MG-132 SDF
分子量 475.62
化学式

C26H41N3O5

CAS No. 133407-82-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
エタノール 95 mg/mL (199.73 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

カスタマーフィードバック (9)


Click to enlarge
Rating
Source Nat Cell Biol, 2015, 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med, 2013, 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep, 2015, 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol, 2012, 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol, 2015, 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett, 2012, 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012, Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

文献中の引用 (42)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related プロテアソーム 阻害剤

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516)が、幅広いスペクトルマトリックス・メタロプロテアーゼ(MMP) MMP-9、MMP-1、MMP-2、MMP-14とMMP-7のための阻害剤です。

  • Ledipasvir (GS5885)

    Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

  • Bortezomib (PS-341)

    Bortezomib (PS-341)は、強力なプロテアソーム阻害剤で、Kiが0.6nMです。

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238)は窒素端加帽の二ペプチドロイシンホウ酸で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位を抑制、IC50が3.4nM、Ki値が0.93nM。

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914(PR-957)は、恒常的プロテアソームのための最小限の交差反応性を持つ強力かつ選択的な免疫プロテアソームの阻害剤です。

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708は二代目経口生物の有効性にプロテアソーム選択阻害剤で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位に作用すると、IC50が3.4nM、Ki値が0.93nMになる。

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

最近チェックしたアイテム

Tags: MG-132を買う | MG-132供給者 | MG-132を購入する | MG-132費用 | MG-132生産者 | オーダーMG-132 | MG-132代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ